BioNano Genomics Inc vs Realty Income Corp — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Realty Income Corp trades at $63.97 (market cap $59.47B). The key difference: Realty Income Corp is far larger — about 4505.3× BioNano Genomics Inc's market cap, and Realty Income Corp pays a 5.1% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | O | |
|---|---|---|
Market Cap | $13.20M | $59.47B |
Sector | Health | Real Estate |
52-Week High | $4.92 | $67.56 |
52-Week Low | $1.09 | $55.93 |
Enterprise Value | $15.81M | $89.27B |
Dividend Yield | — | 5.1% |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Realty Income (O) trades at $64.17, up 1.36% with a bullish technical outlook. The stock shows strong fundamentals with $5.75B revenue and 19.05% net income margin, though recent quarters have missed EPS estimates. Recent credit facility expansion to $5.5B supports growth initiatives, particularly in European markets. Dividend payments remain consistent at $0.27 quarterly, providing stable income for investors.
Outlook remains positive with analyst consensus target of $67.86 representing 5.8% upside. Risks include elevated P/E ratio of 51.89 and three consecutive quarterly earnings misses. The company's expansion strategy and strong cash flow generation support long-term growth potential, though valuation concerns warrant monitoring of future earnings performance.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →